135 related articles for article (PubMed ID: 36001637)
21. Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy.
Zhao B; Yerram NK; Gao T; Dreicer R; Klein EA
Urol Oncol; 2015 Apr; 33(4):164.e19-23. PubMed ID: 25665510
[TBL] [Abstract][Full Text] [Related]
22. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer.
Gomella LG; Zeltser I; Valicenti RK
Urology; 2003 Dec; 62 Suppl 1():46-54. PubMed ID: 14747041
[TBL] [Abstract][Full Text] [Related]
23. Phase 1 trial of neoadjuvant radiation therapy before prostatectomy for high-risk prostate cancer.
Koontz BF; Quaranta BP; Pura JA; Lee WR; Vujaskovic Z; Gerber L; Haake M; Anscher MS; Robertson CN; Polascik TJ; Moul JW
Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):88-93. PubMed ID: 23790772
[TBL] [Abstract][Full Text] [Related]
24. A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients.
Womble PR; VanVeldhuizen PJ; Nisbet AA; Reed GA; Thrasher JB; Holzbeierlein JM
J Urol; 2011 Sep; 186(3):882-7. PubMed ID: 21791342
[TBL] [Abstract][Full Text] [Related]
25. High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.
Cher ML; Shinohara K; Breslin S; Vapnek J; Carroll PR
Br J Urol; 1995 Jun; 75(6):771-7. PubMed ID: 7542137
[TBL] [Abstract][Full Text] [Related]
26. High-risk localised prostate cancer: multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy.
Eastham JA
Expert Opin Emerg Drugs; 2003 Nov; 8(2):291-5. PubMed ID: 14661990
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure.
Meyer F; Moore L; Bairati I; Lacombe L; Têtu B; Fradet Y
J Urol; 1999 Dec; 162(6):2024-8. PubMed ID: 10569561
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant hormonal deprivation for patients undergoing radical prostatectomy.
Gao X; Zhou T; Tang YJ; Lu X; Sun YH
Asian J Androl; 2009 Jan; 11(1):127-30. PubMed ID: 19050694
[TBL] [Abstract][Full Text] [Related]
29. [Neoadjuvant hormonal therapy for prostate cancer].
Miki T; Kamoi K
Gan To Kagaku Ryoho; 2001 Jul; 28(7):927-33. PubMed ID: 11478141
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials.
McKay RR; Berchuck J; Kwak L; Xie W; Silver R; Bubley GJ; Chang PK; Wagner A; Zhang Z; Kibel AS; Taplin ME
J Urol; 2021 Jun; 205(6):1689-1697. PubMed ID: 33502237
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer.
Devos G; Devlies W; De Meerleer G; Baldewijns M; Gevaert T; Moris L; Milonas D; Van Poppel H; Berghen C; Everaerts W; Claessens F; Joniau S
Nat Rev Urol; 2021 Dec; 18(12):739-762. PubMed ID: 34526701
[TBL] [Abstract][Full Text] [Related]
32. [Clinicopathological significance of neoadjuvant hormonal therapy prior to radical prostatectomy: whole section analysis].
Uemura H; Cho M; Hirao Y; Konishi N
Hinyokika Kiyo; 2002 Nov; 48(11):719-23. PubMed ID: 12512148
[TBL] [Abstract][Full Text] [Related]
33. Early use of chemotherapy in conjunction with radical prostatectomy.
Alumkal JJ; Carducci MA
Clin Prostate Cancer; 2004 Dec; 3(3):144-9. PubMed ID: 15636680
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis.
Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
Int J Clin Oncol; 2015 Oct; 20(5):1018-25. PubMed ID: 25681879
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer.
Vuky J; Corman JM; Porter C; Olgac S; Auerbach E; Dahl K
Oncologist; 2013 Jun; 18(6):687-8. PubMed ID: 23740935
[TBL] [Abstract][Full Text] [Related]
36. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy.
Wood DP; Beaman A; Banerjee M; Powell I; Pontes E; Cher ML
Clin Cancer Res; 1998 Sep; 4(9):2119-23. PubMed ID: 9748128
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.
Tiguert R; Rigaud J; Lacombe L; Laverdière J; Fradet Y
J Urol; 2003 Aug; 170(2 Pt 1):447-50. PubMed ID: 12853796
[TBL] [Abstract][Full Text] [Related]
38. Can
Chen M; Zhuang J; Fu Y; Guo S; Zang S; Ai S; Qiu X; Wang F; Guo H
J Urol; 2021 Apr; 205(4):1082-1089. PubMed ID: 33207140
[TBL] [Abstract][Full Text] [Related]
39. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.
McKay RR; Montgomery B; Xie W; Zhang Z; Bubley GJ; Lin DW; Preston MA; Trinh QD; Chang P; Wagner AA; Mostaghel EA; Kantoff PW; Nelson PS; Kibel AS; Taplin ME
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):364-372. PubMed ID: 29263420
[TBL] [Abstract][Full Text] [Related]
40. Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer.
Koshkin VS; Mir MC; Barata P; Gul A; Gupta R; Stephenson AJ; Kaouk J; Berglund R; Magi-Galluzzi C; Klein EA; Dreicer R; Garcia JA
Invest New Drugs; 2019 Jun; 37(3):559-566. PubMed ID: 31037562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
